Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade as cornerstones, emerging therapies such as Bluebird Bio / Celgene’s bb2121 and GlaxoSmithKline's GSK2857916 are pursuing initial approvals for the treatment of multiple myeloma and can expect premium pricing. Further, as a result of expected label expansions of current therapies, multiple myeloma regimens will increasingly include high-priced therapies. Understanding the market access drivers that are important to payers and oncologists will be essential in maximizing these therapies’ uptake.
Survey of 100 hematologist-oncologists in the United States Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
KEY DRUGS COVERED
Current therapies: Darzalex, Empliciti, Kyprolis, Ninlaro, Pomalyst, Revlimid, Velcade
Emerging therapies: bb2121, GSK2857916, subcutaneous Darzalex
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.